



1617

PATENT--NO FEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:)
ANIL GULATI)
Serial No.: 10/659,579)
Filed: September 10, 2003)
For: METHOD AND COMPOSITION FOR)
TREATING ALZHEIMER'S DISEASE AND)
DEMENTIAS OF VASCULAR ORIGIN)
Attorney Docket No. 27611/38545A)
Group Art Unit: 1617)
Examiner: Unassigned)
I hereby certify that this)
paper is being deposited)
with the United States)
Postal Service with suffi-)
cient postage, as first)
class mail, in an envelope)
addressed to:)
Commissioner for Patents)
P.O. Box 1450)
Alexandria, VA 22313-1450)
Dated: April 5, 2004)
James J. Napoli)
Registration No. 32,361)
Attorney for Applicants)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Pursuant to his duty of disclosure under 37 C.F.R. §1.56, applicant hereby brings to the examiner's attention patents and publications that may be material to the examination of the above-identified application. Therefore, in compliance with 37 C.F.R. §1.97 and §1.98, applicant encloses a completed Form PTO-1449 listing the possible pertinent patents and publications and a copy of each patent and publication.

This Supplemental Information Disclosure Statement is submitted more than three months after the filing date of the above-identified application, and, to applicant's knowledge, before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. §1.97(b), this Supplemental Information Disclosure Statement shall be considered by the Patent Office.

In addition, if a first Office Action has been mailed, each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement (37 C.F.R. §1.97(e)(1)). Accordingly, no fee as set forth in 37 C.F.R. §1.17(p) is due.


The Commissioner, however, is hereby authorized to charge any fee which may be required during the pendency of this application under 37 C.F.R. 1.16 or 37 C.F.R. 1.17 to Deposit Account No. 13-2855. A duplicate copy of this Transmittal is enclosed herewith.

A copy of the International Search Report is enclosed for the convenience of the examiner is to complete the file.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

By

A handwritten signature in black ink, appearing to read "James J. Napoli", written over a horizontal line.

James J. Napoli
(Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois
April 5, 2004



Form 1449PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/659,579	
			Filing Date	September 10, 2003	
			First Named Inventor	Anil Gulati	
			Group Art Unit	1617	
			Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	27611/38545A

U.S. PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY
		6,011,019	01/04/2000

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY
		WO 00/54773 (PCT)	09/21/2000
		WO 02/080960 (PCT)	10/17/2002
		0 885 890 (EPO)	12/23/1998

OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Z. Khalil et al., <i>Journal of Alzheimer's Disease</i> , 4, 467-478 (2002).
		S. Schinelli, <i>Current Drug Targets-CNS & Neurological Disorders</i> , 1, 543-553 (2002).
		M. Kohzuki et al., <i>Journal of Cardiovascular Pharmacology</i> , 26 (Suppl. 3), S329-S331 (1995).
		Z. Khalil et al., <i>Brain Research</i> , 736, 206-216 (1996).
		G. Aliev et al., <i>Brain Pathology</i> , Vol. 12, No. 1, 21-35 (2002).
		T. Yagami et al., <i>Brain Research</i> , 948, 72-81 (2002).
		E.A. Eckman et al., <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 27, 24540-24548 (2001).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.